RxDoctor Payments Data

Melissa Peters

Nurse Practitioner · Live Oak, FLNPI 1114439510

Payments from drug & device makers

$769in general payments, 2019–2025

Across 47 payments — averaging $16.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$492
  • Insulet Corporation$102
  • Corcept Therapeutics$84
  • AstraZeneca$26
  • Lilly USA, LLC$19
  • AbbVie$17
  • plus $31 from 2 others

What the payments were for

  • Food & beverage$769100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$769 in reported general payments places this provider in the 70th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$85,093
Medicare patients
229
Services billed
907

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$34,019
EliquisApixaban42$31,267
RybelsusSemaglutide27$29,993
JardianceEmpagliflozin16$19,897
FarxigaDapagliflozin Propanediol27$18,985
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr22$12,932
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$12,275
Tresiba Flextouch U-100Insulin Degludec18$9,701
SymbicortBudesonide/Formoterol Fumarate12$3,407
Atorvastatin Calcium405$3,162
Levothyroxine Sodium283$2,925
Albuterol Sulfate HfaAlbuterol Sulfate67$2,247
Omeprazole152$1,876
Gabapentin126$1,777
SynthroidLevothyroxine Sodium14$1,475

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta$15$46,95159 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$26$34,66757 claims
Novo NordiskRybelsus$492$29,99327 claims
AbbVieSynthroid$17$1,47514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Live Oak

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →